Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval
The PD-L1 inhibitor's label excludes NSCLC patients with EGFR or ALK mutations, which could have been an advantage, but the indication largely reflects the registrational IMpower150 clinical trial's population.
You may also be interested in...
EU OK To Tecentriq-Avastin Combo In NSCLC Includes EGFR-Mutant, ALK-Positive Patients
EU approval of Tecentriq and Avastin together with chemo for the first-line treatment of metastatic non-squamous NSCLC is a positive advance for Roche, but analysts say the combo has a long way to go still to catch up with Merck & Co’s Keytruda combination.
Roche's Tecentriq Steals Lead In Triple-Negative Breast Cancer
The PD-L1 inhibitor is the first checkpoint immunotherapy to gain approval in the tough-to-treat disease setting.
Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors
CEO Ken Frazier had to argue the case that Merck has a diversified portfolio in yet another strong quarter for the PD-1 inhibitor Keytruda.